CD25 antibody | MEM-181
PE conjugated Mouse anti Human CD25 antibody, clone MEM-181 (MCA2127PE) used for the identification of human Tregs by flow cytometry.
Image caption:
Potency of Treg-suppression is dependent on strength of stimulus and on Effector:Treg cell (E:T) ratio. (A) Typical FACS plot displaying purity of effector (CD4+CD25−) and Treg (CD4+CD25+) populations in healthy control subjects. (B) Mean counts per minute (CPM) (+SEM) uptake of tritiated thymidine in CD25− effector T cells from healthy controls (N = 27) stimulated with mitogenic CD3/28 beads at 2:1 and 0.2:1 bead: cell ratios. (C) Mean CPM (+SEM) in CD25− effectors v CD25+ Treg cells stimulated with mitogenic CD3/28 beads at 2:1 bead: cell ratio. (D) Mean (+SEM) percentage suppression of effector cell proliferation following activation with CD3/28 beads at 2:1 (closed boxes) and 0.2:1 (open boxes) bead: cell ratios.
From: Thorborn G, Pomeroy L, Isohanni H, Perry M, Peters B, et al. (2010)
Increased Sensitivity of CD4+ T-Effector Cells to CD4+CD25+ Treg Suppression Compensates for Reduced Treg Number in Asymptomatic HIV-1 Infection.
PLoS ONE 5(2): e9254.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
AlexaFluor®647 conjugated Mouse anti Human CD25 antibody, clone MEM-181 (MCA2127A647) used for the detection of circulating CD25 expressing cells from peripheral blood of SLE patients by flow cytometry.
Image caption:
Detection of circulating CD4+CD25low/-GITR+cells in SLE patients.(A) Flow-cytometry analysis of anti-GITR and anti-CD25-stained CD4+ T lymphocytes, freshly isolated from blood of a representative SLE patient, reveals the presence of a CD25−GITR+ cell subpopulation. Left panel: gating strategy. Gated CD4+ T lymphocytes were stained with isotype control Abs (middle panel) or anti-GITR and anti-CD25 Abs (right panel). (B) the levels of CD25 expression were evaluated in the upper left and lower left quadrants and MFI is reported. (C) mRNA expression of CD25 (FAM6 fluorochrome) in the indicated subpopulations was evaluated in quadruplicate with real-time PCR. In the same tube, expression of the housekeeping gene HPRT1 (VIC fluorochrome) was evaluated for normalization. Values of CD25 expression (striped column, CD25highGITR−; black column, CD25low/-GITR+) is shown as fold increase of mRNA levels in the positively sorted subpopulations over mRNA levels in effector (CD4+CD25−GITR−) T cells, arbitrarily set equal to 1. Data shown are mean ± SD of four SLE patients. ***P <0.001.
From: Nocentini G, Alunno A, Petrillo MG, Bistoni O, Bartoloni E, Caterbi S, Ronchetti S, Migliorati G, Riccardi C, Gerli R.
Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.
Arthritis Res Ther.2014 Sep 26;16(5):444.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human CD25:Alexa Fluor® 488
Mouse anti Human CD25:Alexa Fluor® 647
Mouse anti Human CD25:FITC
Mouse anti Human CD25
Mouse anti Human CD25:RPE
Mouse anti Human CD25:StarBright Blue 700
Mouse anti Human CD25:StarBright Violet 440
Mouse anti Human CD25:StarBright Violet 515
Mouse anti Human CD25:StarBright Violet 610
Mouse anti Human CD25:StarBright Violet 670
Mouse anti Human CD25:StarBright Violet 570
Mouse anti Human CD25:StarBright Violet 710
Mouse anti Human CD25:StarBright Violet 790
- Product Type
- Monoclonal Antibody
- Clone
- MEM-181
- Isotype
- IgG1
| Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|
| MCA2127A488T | F | 25 Tests/0.25ml |
|
|
| MCA2127A488 | F | 100 Tests/1ml |
|
|
| MCA2127A647 | F | 100 Tests/1ml |
|
|
| MCA2127A647T | F | 25 Tests/0.25ml |
|
|
| MCA2127F | F | 0.1 mg |
|
|
| MCA2127FT | F | 25 µg |
|
|
| MCA2127 | F | 0.2 mg |
|
|
| MCA2127PE | F | 100 Tests |
|
|
| MCA2127SBB700 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV440 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV515 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV610 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV670 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV570 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV710 | F | 100 Tests/0.5ml |
|
|
| MCA2127SBV790 | F | 100 Tests/0.5ml |
|
Mouse anti Human CD25, clone MEM-181 recognizes the ~55 kDa alpha subunit of the human IL-2 receptor, also known as p55 or TAC antigen, CD25 is a type 1 transmembrane protein with two Sushi domains, also known as short concensus repeats (SCRs) or complement control protein (CCP) modules (Norman et al. 1991) located within its extracellular domain.
The IL-2 receptor exists in three forms. A high affinity form consisting of a non-covalently linked heterodimer composed of the alpha subunit (CD25) and the IL-2 receptor beta subunit also known as CD122 or p75, a medium affinity beta subunit (CD122) monomer or a low affinity alpha (CD25) subunit monomer.
CD25 is expressed by activated T lymphocytes and activated B lymphocytes responding to antigen or mitogen stimulation. CD25 is also expressed in some thymocytes and oligodendrocytes. In disease, elevated expression of CD25 in noted in a number of chronic inflammatory conditions, tuberculoid leprosy patients demonstrate markedly elevated levels of circulating CD25high FoxP3+ regulatory T cells (T-regs) (Attia et al. 2010).
Elevated levels of CD25 antigen expression are often seen in cases of non-Hodgkin 's lymphoma and diffuse large B cell lymphoma (Fujiwara et al.2013).
The IL-2 receptor exists in three forms. A high affinity form consisting of a non-covalently linked heterodimer composed of the alpha subunit (CD25) and the IL-2 receptor beta subunit also known as CD122 or p75, a medium affinity beta subunit (CD122) monomer or a low affinity alpha (CD25) subunit monomer.
CD25 is expressed by activated T lymphocytes and activated B lymphocytes responding to antigen or mitogen stimulation. CD25 is also expressed in some thymocytes and oligodendrocytes. In disease, elevated expression of CD25 in noted in a number of chronic inflammatory conditions, tuberculoid leprosy patients demonstrate markedly elevated levels of circulating CD25high FoxP3+ regulatory T cells (T-regs) (Attia et al. 2010).
Elevated levels of CD25 antigen expression are often seen in cases of non-Hodgkin 's lymphoma and diffuse large B cell lymphoma (Fujiwara et al.2013).
Product Details
- Target Species
- Human
- Product Form
- Purified IgG conjugated to Alexa Fluor® 488 - liquid
- Product Form
- Purified IgG conjugated to Alexa Fluor® 647 - liquid
- Product Form
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
- Product Form
- Purified IgG conjugated to StarBright Blue 700 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 440 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 515 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 610 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 670 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 570 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 710 - liquid
- Product Form
- Purified IgG conjugated to StarBright Violet 790 - liquid
- Reconstitution
- Reconstitute with 1 ml distilled water
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin - Preservative Stabilisers
0.09% Sodium Azide - Preservative Stabilisers
0.09% Sodium Azide 1% Bovine Serum Albumin 5% Sucrose - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
0.1% Pluronic F68
0.1% PEG 3350
0.05% Tween 20 - Immunogen
- Human PHA blasts; day 3 of culture.
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.05 mg/ml
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse P3.X63 Ag8.653 myeloma cell line.
Storage Information
- Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light. - Storage
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. - Storage
- Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.
DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Storage
- Store at +4°C. DO NOT FREEZE.
This product should be stored undiluted. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P01589
- Entrez Gene
- IL2RA
- GO Terms
- GO:0016021 integral to membrane
- GO:0004911 interleukin-2 receptor activity
- GO:0008283 cell proliferation
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Acknowledgements
- This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
- Regulatory
- For research purposes only
Applications of CD25 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | Neat | 1/5 | |
| Flow Cytometry | Neat | 1/10 | |
| Flow Cytometry | 1/50 | 1/200 | |
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat | ||
| Flow Cytometry | Neat |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
- Flow Cytometry
- Use 5ul of the suggested working dilution to label 106 cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.
Copyright © 2021 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Mouse IgG1 Negative Control:Alexa Fluor® 488 | MCA928A488 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:Alexa Fluor® 647 | MCA928A647 | F | 100 Tests/1ml |
|
|
| Mouse IgG1 Negative Control:FITC | MCA928F | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control | MCA928 | F | 100 Tests |
|
|
| Mouse IgG1 Negative Control:RPE | MCA928PE | F | 100 Tests |
|
Useful Reagents Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test | ||
| Human Seroblock | BUF070A | F | 50 Test | ||
| Human Seroblock | BUF070B | F | 200 Test |
Product Specific References
References for CD25 antibody
-
Prager, E. et al. (2001) Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor:ligand pathway in T cells.
J Immunol. 166 (4): 2364-71. -
Thorborn, G. et al. (2010) Increased sensitivity of CD4+ T-effector cells to CD4+CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection.
PLoS One. 5: e9254. -
Cutler, A.J. et al. (2010) Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation.
J Immunol. 185: 6617-23. -
Lawson, J.M. et al. (2008) Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes.
Clin Exp Immunol. 154: 353-9. -
Holderness, J. et al. (2007) Select plant tannins induce IL-2Ralpha up-regulation and augment cell division in gammadelta T cells.
J Immunol. 179: 6468-78. -
Zhang, Y. et al. (2013) Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism.
PLoS Pathog. 9 (4): e1003310. -
Nocentini, G. et al. (2014) Expansion of regulatory GITR + CD25 Low/- CD4 + T cells in systemic lupus erythematosus patients.
Arthritis Res Ther. 16: 444. -
Soukup, K. et al. (2015) The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis.
J Immunol. 195 (2): 541-52. -
Kusunoki, Y. et al. (2010) T-cell immunosenescence and inflammatory response in atomic bomb survivors.
Radiat Res. 174 (6): 870-6. -
Bughani, U. et al. (2017) T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
PLoS One. 12 (7): e0180088. -
Knutson, K.L. et al. (2015) Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
Cancer Immunol Immunother. 64 (12): 1495-504. -
Boland, J.W. et al. (2014) A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function.
BMJ Support Palliat Care. 4 (4): 357-67. -
Luger, R. et al. (2013) Toll-like receptor 4 engagement drives differentiation of human and murine dendritic cells from a pro- into an anti-inflammatory mode.
PLoS One. 8 (2): e54879.
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸How to Use the Spectraviewer
Watch the Tool Tutorial Video ▸- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra
